Importantly, TIGIT is considered a promising target for its immunomodulatory role in carcinogenesis; at the same time, CD155/TIGIT, a novel immune checkpoint in human cancers, can exert inhibitory effect on PI3K/MAPK signaling, NF-κB signaling, and AKT/mTOR signaling, which lead to downregulate metabolism, suppress cytokine production, and inhibited NK cell cytotoxicity [15, 58]. This evidence concerns the gene AKT1 and cancer.